Search Clinical Trials

A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

MIRATI-1719-001

Cancer, Other Skin, Thoracic Cancers, Gynecologic Cancers, Other Gastrointestinal, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Melanoma, Skin, Esophagus, Bladder, Pancreas/Liver, Prostate, Skin Cancers, Kidney, Prostate and Urologic Cancers, Head and Neck Cancers, Colorectal, Gastrointestinal Cancers, Sarcoma, Breast Cancers

An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations

LOXO-J5M-OX-JOXA

Cancer, Stomach, Prostate, Breast Cancers, Other Skin, Lip, Oral Cavity and Pharynx, Larynx, Ovary, Head and Neck Cancers, Thoracic Cancers, Sarcoma, Other Urologic, Pancreas/Liver, Cervix, Gynecologic Cancers, Esophagus, Melanoma, Skin, Bladder, Gastrointestinal Cancers, Prostate and Urologic Cancers, Early Phase/Multiple Disease Site Cancers, Skin Cancers

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

SWOG-S2012

Cancer, Colorectal, Other Gastrointestinal, Prostate, Pancreas/Liver, Ovary, Early Phase/Multiple Disease Site Cancers, Bladder, Prostate and Urologic Cancers, Gynecologic Cancers, Gastrointestinal Cancers

Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

MERCK-MK-5684-01A

Cancer, Prostate, Prostate and Urologic Cancers

The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.

DAIICHI-SANKYO-DS3939-077

Cancer, Kidney, Skin Cancers, Stomach, Uterine, Lung, Other Urologic, Head and Neck Cancers, Esophagus, Thoracic Cancers, Ovary, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Prostate, Prostate and Urologic Cancers, Cervix, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Breast Cancers

Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

MONTERIS-CL10153-REMASTER

Cancer, Endocrine Cancers, Uterine, Other Urologic, Colorectal, Cervix, Lung, Brain and Spine Cancers, Prostate, Stomach, Skin Cancers, Prostate and Urologic Cancers, Other Respiratory, Gastrointestinal Cancers, Breast Cancers, Head and Neck Cancers, Esophagus, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NRG-BN013

Cancer, Other Skin, Bladder, Colorectal, Cervix, Other Gynecologic, Breast Cancers, Esophagus, Prostate, Larynx, Other Gastrointestinal, Esophagus, Gynecologic Cancers, Other Respiratory, Melanoma, Skin, Prostate and Urologic Cancers, Pancreas/Liver, Eye/Orbital Cancers, Thoracic Cancers, Lip, Oral Cavity and Pharynx, Head and Neck Cancers, Gastrointestinal Cancers, Endocrine Cancers, Skin Cancers, Brain and Spine Cancers

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

MERCK-MK-5684-003

Cancer, Prostate, Prostate and Urologic Cancers

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (PREDICT)

ALLIANCE-A032102

Cancer, Prostate, Prostate and Urologic Cancers

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

ALLIANCE-A032302-ASPIRE

Cancer, Prostate, Prostate and Urologic Cancers